Recent Securities Litigations

Spero Therapeutics Inc. Common Stock (NASDAQ: SPRO)

29 Days left to seek lead plaintiff status.

Company Name:Spero Therapeutics Inc. Common Stock
Stock Symbol:NASDAQ: SPRO
Class Period Start:10/28/2021
Class Period End (inclusive):05/02/2022
Filing Deadline:07/25/2022

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the data submitted in support of the Tebipenem HBr NDA were insufficient to obtain FDA approval; (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero’s operations; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Spero Therapeutics Inc. Common Stock (NASDAQ: SPRO) Claim Form

Name(Required)
Address
Consent(Required)
This field is for validation purposes and should be left unchanged.